ArticleInternational journal of radiation oncology, biology, physics2014
Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer.
Article in International journal of radiation oncology, biology, physics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer.The British journal of radiology · 2017Pooled it
- Re-irradiation in lung disease by SBRT: a retrospective, single institutional study.Radiation oncology (London, England) · 2018Trial
- Re-irradiation for locoregionally recurrent tumors of the thorax: a single-institution, retrospective study.Radiation oncology (London, England) · 2016Trial
- Re-irradiation in central lung cancer-a monocentric detailed analysis.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Single-center experience in combined video-assisted thoracic surgery with transbronchial microwave ablation-a novel approach to multifocal lung nodules.Frontiers in surgery · 2026Article
- Outcomes and Toxicity following 3 or More Definitive Courses of Thoracic Radiation Therapy for Non-Small Cell Lung Cancer.Clinical lung cancer · 2025Article
- Review
- Reirradiation of Utracentrally Located Thoracic Tumors Using a 10-Fraction Hypofractionated Stereotactic Body Radiation Therapy Course: A Detailed Dosimetric Analysis.Advances in radiation oncology · 2024Article
- Salvage Reirradiation with Proton Beam Therapy for Locoregionally Recurrent Non-Small Cell Lung Cancer.Cancers · 2024Article
- Re-irradiation for intra-thoracic tumours and extra-thoracic breast cancer: dose accumulation, evaluation of efficacy and toxicity based on a literature review.The British journal of radiology · 2022Review
- Toxicity of Proton Therapy versus Photon Therapy on Salvage Re-Irradiation for Non-Small Cell Lung Cancer.Life (Basel, Switzerland) · 2022Article
- An algorithm for thoracic re-irradiation using biologically effective dose: a common language on how to treat in a "no-treat zone".Radiation oncology (London, England) · 2022Article
- Treatment outcomes of re-irradiation using stereotactic ablative radiotherapy to lung: a propensity score matching analysis.Radiation oncology (London, England) · 2021Article
- Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma?International journal of radiation oncology, biology, physics · 2021Review
- Salvage proton beam therapy for locoregional recurrence of non-small cell lung cancer.Radiation oncology journal · 2021Article
- A Retrospective Study on Using a Novel Single Needle Cone Puncture Approach for the Iodine-125 Seed Brachytherapy in Treating Patients With Thoracic Malignancy.Frontiers in oncology · 2021Article
- A long-term survival case following salvage stereotactic radiotherapy for local recurrence after definitive chemoradiotherapy for stage III non-small cell lung cancer.International cancer conference journal · 2020Article
- Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer.Clinical and translational radiation oncology · 2020Article
- Repeat stereotactic body radiation therapy (SBRT) for salvage of isolated local recurrence after definitive lung SBRT.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2020Article
- Safety and efficacy of CT-guided radioactive iodine-125 seed implantation assisted by a 3D printing template for the treatment of thoracic malignancies.Journal of cancer research and clinical oncology · 2020Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo retrospectively assess toxicity and outcome of re-irradiation with stereotactic body radiation therapy (SBRT) in patients with recurrent or persistent non-small cell lung cancer (NSCLC), who were previously treated with radical radiation therapy (50-60 Gy). The secondary endpoint was to investigate whether there are dosimetric parameter predictors of severe radiation toxicity. METHODS AND MATERIALS: The analysis was conducted in 17 patients with "in-field" recurrent/persistent centrally located NSCLC, who underwent re-irradiation with SBRT. SBRT consisted of 30 Gy in 5 to 6 fractions; these prescriptions would be equivalent for the tumor to 37.5 to 40 Gy, bringing the total 2-Gy-per-fraction cumulative dose to 87 to 100 Gy, considering the primary radiation therapy treatment. Actuarial analyses and survival were calculated by the Kaplan-Meier method, and P values were estimated by the log-rank test, starting from the date of completion of SBRT. Dosimetric parameters from the subgroups with and without grade ≥3 pulmonary toxicity were compared using a 2-tailed Student t test.
resultsThe median follow-up was 18 months (range, 4-57 months). Only 2 patients had local failure, corresponding to a local control rate of 86% at 1 year. The Kaplan-Meier estimates of overall survival (OS) rates at 1 and 2 years were 59% and 29%, respectively; the median OS was 19 months. Four patients (23%) experienced grade 3 radiation pneumonitis, and 1 patient developed fatal pneumonitis. One patient died of fatal hemoptysis 2 months after the completion of SBRT. Unexpectedly, heart maximum dose, D5 (minimum dose to at least 5% of the heart volume), and D10 were correlated with risk of radiation pneumonitis (P<.05).
conclusionsRe-irradiation with SBRT for recurrent/persistent centrally located NSCLC achieves excellent results in terms of local control. However, the high rate of severe toxicity reported in our study is of concern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.